Lysergic acid diethylamide

The DEA proposed increasing psilocybin, psilocin, and ibogaine production quotas by 50% for 2025, signaling support for psychedelic research. This follows a growing interest in studying these compounds for mental health treatments, despite their Schedule 1 status. The VA is also increasingly involved in psychedelic-assisted therapy research for veterans.

Water Tower Research published a report on Cybin, Inc., highlighting its leadership in neuropsychiatric therapeutics, rapid advancement of lead candidates CYB003 and CYB004, and differentiated deuteration technology. Cybin's market valuation is favorable compared to peers, and its well-capitalized status positions it for potential success.

Water Tower Research published an Initiation of Coverage Report on Cybin, Inc., highlighting its status as a leader in novel neuropsychiatric therapeutics. Cybin's focus on innovative treatments for mental health disorders like MDD and GAD, with lead candidates CYB003 and CYB004, positions it favorably compared to peers. The report emphasizes Cybin's rapid pipeline advancement and differentiated solutions, noting its favorable valuation and well-capitalized status.

Psychedelic drugs are nearing prescription for European patients with mental health issues, but hurdles remain. Research on psilocybin and MDMA is ongoing, with potential to treat conditions like depression and addiction. Controversy and challenges in study replication persist, but larger-scale studies and advances in brain scan technology are providing clearer insights. The first psychedelic to hit the European market may be from UK-based Compass Pathways, which is testing psilocybin for treatment-resistant depression. The psychedelic movement faces setbacks, such as US regulators rejecting MDMA for PTSD, which could delay access in Europe.

Congressional lawmakers seek public input on creating a regulatory framework for psychedelic therapies, emphasizing the need for inclusive, responsible, and ethical use, and considering the cultural practices of indigenous communities.

Psychiatry faces a high-stakes experiment with psychedelics, which could revolutionize treatments but risks damaging credibility if unsuccessful. The field nearly faced extinction in the 1960s due to anti-psychiatry movements and Freudian disenchantment, but was saved by scientific method. Now, psychedelics, once banned, are being reconsidered for their therapeutic potential, though concerns remain about scientific rigor and commercial opportunism.

Mindstate Design Labs gains FDA and EMA approval for human trials of MSD-001, a neurotech AI-designed compound targeting specific serotonin receptors. The Phase 1 trials, to be held in Leiden, will assess safety and neural impacts using advanced techniques. Mindstate's Osmanthus platform integrates AI with 70,000 drug reports and biochemical data to design precise psychoactive effects.

Researchers believe psychedelics could treat mental health, with ongoing trials in UK and worldwide. Psilocybin shows most evidence for effectiveness, with potential benefits beyond serious conditions. Despite tight UK control, businesses invest in psychedelic treatments, anticipating global authorization.

Psilera's PSIL-006, a non-psychedelic psilocybin-based drug, shows promise in treating frontotemporal dementia (FTD) with a strong safety profile in preclinical studies, potentially paving the way for FDA approval and addressing a critical need in dementia care.

Classic psychedelics like LSD and psilocybin are well-tolerated in clinical settings, with serious adverse events being rare, according to a study in JAMA Psychiatry. However, incomplete adverse event reporting highlights the need for improved safety monitoring. The study found no serious adverse events among healthy participants, but about 4% of those with neuropsychiatric disorders experienced serious events. The research emphasizes the need for rigorous pharmacovigilance practices to accurately quantify risks and benefits.